RxDoctor Payments Data

Joseph Hope, DO

Internal Medicine · Media, PANPI 1699743377

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 72 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$317
  • Johnson & Johnson$130
  • Lilly USA, LLC$112
  • AbbVie$84
  • Merck$78
  • Novo Nordisk$75
  • plus $351 from 13 others

What the payments were for

  • Speaking & faculty fees$272%
  • Food & beverage$1,11998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,147 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$422,363
Medicare patients
356
Services billed
3,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban488$148,927
XareltoRivaroxaban185$52,571
JanuviaSitagliptin Phosphate32$26,040
GemtesaVibegron94$23,518
MyrbetriqMirabegron39$18,904
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,203
JardianceEmpagliflozin12$17,619
EntrestoSacubitril/Valsartan54$16,138
Atorvastatin Calcium661$6,501
Levothyroxine Sodium725$6,263
RytaryCarbidopa/Levodopa32$6,232
RestasisCyclosporine16$5,530
Rosuvastatin Calcium222$5,187
Imatinib Mesylate35$5,105
Metoprolol Succinate417$4,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$130$52,571185 claims
MerckJanuvia$78$26,04032 claims
Sumitomo Pharma America, Inc.Gemtesa$36$23,51894 claims
Astellas Pharma US IncMyrbetriq$13$18,90439 claims
NovartisEntresto$12$16,13854 claims
AbbVieRestasis$84$5,53016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →